EP08.02-068 ALK-Dependent Resistance Mechanism to Ensartinib Differs Between the ALK Fusion Subtypes Variant 1 (V1) and Variant 3 (V3)

Abstract

Ensartinib is a next-generation (NG) ALK TKI that showed comparable efficacy to other NG ALK TKIs in the first-line and post-crizotinib settings. We have reported that ensartinib has similar efficacy between ALK fusion subtypes V1 and V3, and their median PFS were 5.5 (4.2, 7.7) and 6.6 (4.1, 9.8) months, respectively. Here, we further explored the ALK-dependent resistance mechanisms of these two subtypes.